Western Pacific Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Western Pacific Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.07K	Hold	1,000	–	–	﹤0.01%	171
2025 Q4	$4.09K	Buy	+1,000	New	+$4.95K	﹤0.01%	159
2025 Q1	–	Sell	-20	Closed	-$135	–	207
2024 Q4	$135	Hold	20	–	–	﹤0.01%	208
2024 Q3	$132	Hold	20	–	–	﹤0.01%	253
2024 Q2	$150	Hold	20	–	–	﹤0.01%	228
2024 Q1	$199	Hold	20	–	–	﹤0.01%	302
2023 Q4	$197	Hold	20	–	–	﹤0.01%	240
2023 Q3	$153	Hold	20	–	–	﹤0.01%	273
2023 Q2	$149	Hold	20	–	–	﹤0.01%	278
2023 Q1	$133	Hold	20	–	–	﹤0.01%	300
2022 Q4	$154	Buy	+20	New	+$196	﹤0.01%	286

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Western Pacific Wealth Management's RXRX Position: Q1 2026 in Review

Western Pacific Wealth Management held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 1,000 shares worth $3.07K. The position accounts for ﹤0.01% of the portfolio, ranked #171.

Western Pacific Wealth Management first reported a position in RXRX in Q4 2022 and has held it in 11 quarters since. The position peaked at $4.09K in Q4 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Western Pacific Wealth Management held 1,000 shares of Recursion Pharmaceuticals worth $3.07K as of Q1 2026.
Western Pacific Wealth Management left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Western Pacific Wealth Management's portfolio in Q1 2026, its #171 holding.
Western Pacific Wealth Management first reported a position in Recursion Pharmaceuticals in Q4 2022 and has held it in 11 quarters since.
Western Pacific Wealth Management's Recursion Pharmaceuticals position peaked at $4.09K in Q4 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Western Pacific Wealth Management's 13F filing for Q1 2026, filed 17 Apr 2026.